世界の進行性家族性肝内胆汁うっ滞症2型治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5963
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、109ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、進行性家族性肝内胆汁うっ滞症2型治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ウルソデオキシコール酸、コレスチラミン、リファンピシン、後期パイプライン薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・進行性家族性肝内胆汁うっ滞症2型治療の市場動向
・企業の競争状況、市場シェア
・進行性家族性肝内胆汁うっ滞症2型治療の種類別市場規模と予測2016-2027（ウルソデオキシコール酸、コレスチラミン、リファンピシン、後期パイプライン薬、その他）
・進行性家族性肝内胆汁うっ滞症2型治療の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局）
・進行性家族性肝内胆汁うっ滞症2型治療の北米市場規模2016-2027（アメリカ、カナダ）
・進行性家族性肝内胆汁うっ滞症2型治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・進行性家族性肝内胆汁うっ滞症2型治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・進行性家族性肝内胆汁うっ滞症2型治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・進行性家族性肝内胆汁うっ滞症2型治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Teva、AbbVie、Glenmark Pharmaceuticals、Par Pharmaceuticals、Mylan、Sanofi、Novartis、Akorn、Albireo Pharma、Mirum Pharmaceuticals）
・結論

Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs.

Market Analysis and Insights: Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market.

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Scope and Market Size
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Ursodeoxycholic Acid
1.2.3 Cholestyramine
1.2.4 Rifampicin
1.2.5 Late Stage Pipeline Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Perspective (2016-2027)
2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Trends by Regions
2.2.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Dynamic
2.3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Trends
2.3.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers
2.3.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Challenges
2.3.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Revenue
3.1.1 Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Revenue (2016-2021)
3.1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue
3.4 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Ratio
3.4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2020
3.5 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Key Players Head office and Area Served
3.6 Key Players Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Solution and Service
3.7 Date of Enter into Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Breakdown Data by Type
4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Type (2016-2021)
4.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2022-2027)

5 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Breakdown Data by Application
5.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Application (2016-2021)
5.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2016-2027)
6.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
6.2.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021)
6.2.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027)
6.2.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2027)
6.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
6.3.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021)
6.3.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027)
6.3.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2027)
6.4 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
6.4.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021)
6.4.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2016-2027)
7.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
7.2.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021)
7.2.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027)
7.2.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2027)
7.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
7.3.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021)
7.3.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027)
7.3.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2027)
7.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
7.4.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021)
7.4.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2016-2027)
8.2 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
8.2.1 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
8.3.1 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region
8.4.1 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2016-2027)
9.2 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
9.2.1 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2027)
9.3 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
9.3.1 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2027)
9.4 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
9.4.1 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2016-2027)
10.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
10.2.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
10.3.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
10.4.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Details
11.1.2 Teva Business Overview
11.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.1.4 Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.1.5 Teva Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Details
11.2.2 AbbVie Business Overview
11.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.2.4 AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.2.5 AbbVie Recent Development
11.3 Glenmark Pharmaceuticals
11.3.1 Glenmark Pharmaceuticals Company Details
11.3.2 Glenmark Pharmaceuticals Business Overview
11.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.3.4 Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.3.5 Glenmark Pharmaceuticals Recent Development
11.4 Par Pharmaceuticals
11.4.1 Par Pharmaceuticals Company Details
11.4.2 Par Pharmaceuticals Business Overview
11.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.4.4 Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.4.5 Par Pharmaceuticals Recent Development
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.5.4 Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.5.5 Mylan Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.6.4 Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.6.5 Sanofi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.7.4 Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Akorn
11.8.1 Akorn Company Details
11.8.2 Akorn Business Overview
11.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.8.4 Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.8.5 Akorn Recent Development
11.9 Albireo Pharma
11.9.1 Albireo Pharma Company Details
11.9.2 Albireo Pharma Business Overview
11.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.9.4 Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.9.5 Albireo Pharma Recent Development
11.10 Mirum Pharmaceuticals
11.10.1 Mirum Pharmaceuticals Company Details
11.10.2 Mirum Pharmaceuticals Business Overview
11.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.10.4 Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
11.10.5 Mirum Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Ursodeoxycholic Acid
Table 3. Key Players of Cholestyramine
Table 4. Key Players of Rifampicin
Table 5. Key Players of Late Stage Pipeline Drugs
Table 6. Key Players of Others
Table 7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Regions (2016-2021)
Table 11. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Regions (2022-2027)
Table 13. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Trends
Table 14. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers
Table 15. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Challenges
Table 16. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Restraints
Table 17. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Players (2016-2021)
Table 19. Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2020)
Table 20. Ranking of Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Solution and Service
Table 24. Date of Enter into Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Teva Company Details
Table 65. Teva Business Overview
Table 66. Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 67. Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 68. Teva Recent Development
Table 69. AbbVie Company Details
Table 70. AbbVie Business Overview
Table 71. AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 72. AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 73. AbbVie Recent Development
Table 74. Glenmark Pharmaceuticals Company Details
Table 75. Glenmark Pharmaceuticals Business Overview
Table 76. Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 77. Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 78. Glenmark Pharmaceuticals Recent Development
Table 79. Par Pharmaceuticals Company Details
Table 80. Par Pharmaceuticals Business Overview
Table 81. Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 82. Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 83. Par Pharmaceuticals Recent Development
Table 84. Mylan Company Details
Table 85. Mylan Business Overview
Table 86. Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 87. Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 88. Mylan Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 92. Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 97. Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 98. Novartis Recent Development
Table 99. Akorn Company Details
Table 100. Akorn Business Overview
Table 101. Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 102. Akorn Recent Development
Table 103. Albireo Pharma Company Details
Table 104. Albireo Pharma Business Overview
Table 105. Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 106. Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 107. Albireo Pharma Recent Development
Table 108. Mirum Pharmaceuticals Company Details
Table 109. Mirum Pharmaceuticals Business Overview
Table 110. Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 111. Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021) & (US$ Million)
Table 112. Mirum Pharmaceuticals Recent Development
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type: 2020 VS 2027
Figure 2. Ursodeoxycholic Acid Features
Figure 3. Cholestyramine Features
Figure 4. Rifampicin Features
Figure 5. Late Stage Pipeline Drugs Features
Figure 6. Others Features
Figure 7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Report Years Considered
Figure 12. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Regions (2022-2027)
Figure 16. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Players in 2020
Figure 17. Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2020
Figure 19. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2016-2027)
Figure 23. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2016-2027)
Figure 24. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2016-2027)
Figure 25. United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2016-2027)
Figure 29. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2016-2027)
Figure 30. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2016-2027)
Figure 31. Germany Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2016-2027)
Figure 41. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Teva Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 62. Glenmark Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 63. Par Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 64. Mylan Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 65. Sanofi Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 67. Akorn Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 68. Albireo Pharma Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 69. Mirum Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界の家族性大腸腺腫症治療市場規模・現状・予測（2021年-2027年）

Global Familial Adenomatous Polyposis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5736 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、家族性大腸腺腫症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（イコサペント、塩酸エフロルニチン、アスピリン、CEQ-508、その他）、用途別市場規模（診療所、病院、その他）、主要地域別市場規模（...

世界のホモ接合型家族性高コレステロール血症疫学市場規模・現状・予測（2021年-2027年）

Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size, Status and Forecast 2021-2027
QFJ1-4318 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、ホモ接合型家族性高コレステロール血症疫学の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（スタチン、MTP阻害剤（ロミタピド）、PCSK9阻害剤、その他）、用途別市場規模（病院、研究所、商業用、その他）...

世界の進行性核上性麻痺市場規模・現状・予測（2021年-2027年）

Global Progressive Supranuclear Palsy Market Size, Status and Forecast 2021-2027
QFJ1-5964 2021年6月 108Pages
QYResearch社発行の本調査レポートでは、進行性核上性麻痺の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（初期段階、臨床試験、後期段階、その他）、用途別市場規模（病院、クリニック、研究所、その他）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の睡眠麻痺治療市場規模・現状・予測（2021年-2027年）

Global Sleep Paralysis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4872 2021年6月 86Pages
QYResearch社発行の本調査レポートでは、睡眠麻痺治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（覚醒剤、選択的セロトニン再取り込み阻害薬（SSRI）、三環系抗うつ薬、オキシベートナトリウム）、用途別市場規模（病院、家庭、介護センター、そ...

世界の周産期感染症治療市場規模・現状・予測（2021年-2027年）

Global Perinatal Infections Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4682 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、周産期感染症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、抗ウイルス剤）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国...

世界のバッテン病治療市場規模・現状・予測（2021年-2027年）

Global Batten Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3891 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、バッテン病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（作業療法、理学療法）、用途別市場規模（乳児NCL、後期乳児NCL、少年NCL、成人NCL）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界の女性化乳房治療市場規模・現状・予測（2021年-2027年）

Global Gynecomastia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4275 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、女性化乳房治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、手術治療）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界のレット症候群治療市場規模・現状・予測（2021年-2027年）

Global Rett Syndrome Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5994 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、レット症候群治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗てんかん薬、抗てんかん薬、鎮静催眠薬、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、...

世界の失読症治療市場規模・現状・予測（2021年-2027年）

Global Dyslexia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4165 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、失読症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、運動治療、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界のアメーバ症治療市場規模・現状・予測（2021年-2027年）

Global Amebiasis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3791 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、アメーバ症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（メトロニダゾール、パロモマイシン、チニダゾール、その他）、用途別市場規模（病院、薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、...

世界の家族性大腸腺腫症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Familial Adenomatous Polyposis Treatment Market The global Familial Adenomatous Polyposis Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analys…
世界の後期慢性腎臓病治療薬市場規模・現状・予測（2021年-2027年） Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia. Market Analysis and Insights: Global Late Stage Chronic Kidney Disease Drugs Market The global Late Stage …
世界のホモ接合型家族性高コレステロール血症疫学市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Homozygous Familial Hypercholesterolemia Epidemiology Market The global Homozygous Familial Hypercholesterolemia Epidemiology market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-s…
世界の進行性核上性麻痺市場規模・現状・予測（2021年-2027年） Progressive Supranuclear Palsy is a class of neuro-degenerative disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. Market Analysis and Insights: Global Progressive Supranuclear Palsy Market The global Progressive Supranuclear …
世界のウイルス性肺炎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Viral Pneumonia Treatment Drugs Market The global Viral Pneumonia Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data i…